[Lipoprotein(a) is associated to atherosclerosis in primary hypercholesterolemia]

Clin Investig Arterioscler. 2014 Jul-Aug;26(4):176-83. doi: 10.1016/j.arteri.2014.01.001. Epub 2014 Feb 25.
[Article in Spanish]

Abstract

Introduction: Several studies have suggested that Lp(a) could be a risk factor mainly in hypercholesterolemic patients.

Methods: A total of 909 individuals were selected for this study. 307 were diagnosed of familiar hypercholesterolemia with a pathogenic mutation in LDLR or APOB genes (FH+), 291 of familiar combined hyperlipidemia (FCH) and 311 of familial hypercholesterolemia without a pathogenic mutation in LDLR nor APOB genes (FH-). Main risk factor were studied, included statin treatment. Plasma lipids, Lp(a), HbA1c and C-reactive protein. Intima-media thickness (IMT) of common and bulb carotid in both sides were measured in all subjects.

Results: Lp(a) values (median, interquartile range) were 21.9mg/dL (9.24-50.5) in FH+, 22.4mg/dL (6.56-51.6) in FCH and 32.7 (14.6-71.5) in FH- (P<.001). Regression analysis including age, gender, HDL cholesterol, LDL cholesterol corrected for Lp(a), Lp(a), C-reactive protein, packs of cigarettes/day per year, systolic blood pressure and glucose as independent variables, demonstrate that Lp(a) was associated with carotid IMT in FH- subjects. Cardiovascular disease was more frequent in subjects with Lp(a) >50mg/dL (17.9%) than in subjects with Lp(a) <15mg/dL (9.6%), and between 15-50mg/dL (10.1%), and it was concentrated mostly in FH-group (6.7, 11.3, and 23.4% for the groups of Lp(a) <15mg/dL 15-50mg/dL, and >50mg/dL, respectively).

Conclusions: Our results indicate that Lp(a) is associated with atherosclerosis burden especially in subjects with FH- and concentrations of Lp(a)>50mg/dL.

Keywords: Cardiovascular disease; Carotid intima-media thickness; Enfermedad cardiovascular; Grosor íntima-media carotídeo; Lipoprotein(a); Lipoproteína(a).

Publication types

  • English Abstract
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Atherosclerosis / epidemiology
  • Atherosclerosis / etiology*
  • Blood Pressure / physiology
  • C-Reactive Protein / metabolism
  • Cardiovascular Diseases / epidemiology
  • Carotid Intima-Media Thickness
  • Cholesterol, HDL / blood
  • Cholesterol, LDL / blood
  • Female
  • Glucose / metabolism
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Hypercholesterolemia / complications*
  • Hypercholesterolemia / genetics
  • Hypercholesterolemia / physiopathology
  • Hyperlipoproteinemia Type II / complications*
  • Hyperlipoproteinemia Type II / drug therapy
  • Hyperlipoproteinemia Type II / physiopathology
  • Lipoprotein(a) / metabolism*
  • Male
  • Middle Aged
  • Mutation
  • Receptors, LDL / genetics
  • Regression Analysis
  • Risk Factors

Substances

  • Cholesterol, HDL
  • Cholesterol, LDL
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Lipoprotein(a)
  • Receptors, LDL
  • C-Reactive Protein
  • Glucose